182 related articles for article (PubMed ID: 28801709)
1. DEX implant intravitreal injection, sustained intraocular hypertension, and steroid-induced glaucoma in patients with no risk factors.
Rezkallah A; Kodjikian L; Malclès A; Dot C
Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):219-220. PubMed ID: 28801709
[No Abstract] [Full Text] [Related]
2. SAFETY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX): The SAFODEX study. Incidence and Risk Factors of Ocular Hypertension.
Malclès A; Dot C; Voirin N; Vié AL; Agard É; Bellocq D; Denis P; Kodjikian L
Retina; 2017 Jul; 37(7):1352-1359. PubMed ID: 27768641
[TBL] [Abstract][Full Text] [Related]
3. LONG-TERM INCIDENCE AND RISK FACTORS OF OCULAR HYPERTENSION FOLLOWING DEXAMETHASONE-IMPLANT INJECTIONS: THE SAFODEX-2 STUDY.
Rezkallah A; Mathis T; Abukhashabah A; Voirin N; Malclès A; Agard É; Lereuil T; Denis P; Dot C; Kodjikian L
Retina; 2021 Jul; 41(7):1438-1445. PubMed ID: 33315814
[TBL] [Abstract][Full Text] [Related]
4. XEN Gel Stent to Treat Intraocular Hypertension After Dexamethasone-Implant Intravitreal Injections: 5 Cases.
Rezkallah A; Mathis T; Denis P; Kodjikian L
J Glaucoma; 2019 Jan; 28(1):e5-e9. PubMed ID: 30234749
[TBL] [Abstract][Full Text] [Related]
5. INTRAOCULAR DEXAMETHASONE IMPLANT POSITION IN SITU AND OCULAR HYPERTENSION.
Sudhalkar A; Kodjikian L; Chhablani J; Bhojwani D; Vasavada A
Retina; 2018 Dec; 38(12):2343-2349. PubMed ID: 29016454
[TBL] [Abstract][Full Text] [Related]
6. Intraocular pressure fluctuation following intravitreal dexamethasone implant and incidence of secondary ocular hypertension: a Zambian perspective.
Raj P; Kumar K; Balasubramaniam S; Geetha CS; Agarwal A
Pan Afr Med J; 2021; 39():108. PubMed ID: 34512844
[TBL] [Abstract][Full Text] [Related]
7. Secondary Ocular Hypertension and the Risk of Glaucoma Surgery After Dexamethasone Intravitreal Implant in Routine Clinical Practice.
Hemarat K; Kemmer JD; Porco TC; Eaton AM; Khurana RN; Stewart JM
Ophthalmic Surg Lasers Imaging Retina; 2018 Sep; 49(9):680-685. PubMed ID: 30222802
[TBL] [Abstract][Full Text] [Related]
8. Incidence, Risk Factors, Treatment, and Outcome of Ocular Hypertension following Intravitreal Steroid Injections: A Comparative Study.
Badrinarayanan L; Rishi P; George R; Isaac N; Rishi E;
Ophthalmologica; 2022; 245(5):431-438. PubMed ID: 35468616
[TBL] [Abstract][Full Text] [Related]
9. Ocular Hypertension Following Intravitreal Injection of 0.7mg Dexamethasone Implant versus 2mg Triamcinolone.
Kuley B; Storey PP; Pancholy M; Obeid A; Murphy J; Goodman J; Wibbelsman TD; Regillo C; Chiang A
Semin Ophthalmol; 2020 Feb; 35(2):141-146. PubMed ID: 32343619
[No Abstract] [Full Text] [Related]
10. OBSERVED COMPLICATIONS FROM DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF MACULAR EDEMA IN RETINAL VEIN OCCLUSION OVER 3 TREATMENT ROUNDS.
Reid GA; Sahota DS; Sarhan M
Retina; 2015 Aug; 35(8):1647-55. PubMed ID: 25932545
[TBL] [Abstract][Full Text] [Related]
11. Effect of intravitreal injection of dexamethasone 0.7 mg (Ozurdex®) on intraocular pressure in patients with macular edema.
Mazzarella S; Mateo C; Freixes S; Burés-Jelstrup A; Rios J; Navarro R; García-Arumí J; Corcóstegui B; Arrondo E
Ophthalmic Res; 2015; 54(3):143-9. PubMed ID: 26394206
[TBL] [Abstract][Full Text] [Related]
12. Age as a risk factor for steroid-induced ocular hypertension in the non-paediatric population.
Choi W; Bae HW; Choi EY; Kim M; Kim EW; Kim CY; Kim M; Seong GJ
Br J Ophthalmol; 2020 Oct; 104(10):1423-1429. PubMed ID: 32071035
[TBL] [Abstract][Full Text] [Related]
13. INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY.
Maturi RK; Pollack A; Uy HS; Varano M; Gomes AM; Li XY; Cui H; Lou J; Hashad Y; Whitcup SM;
Retina; 2016 Jun; 36(6):1143-52. PubMed ID: 26871523
[TBL] [Abstract][Full Text] [Related]
14. OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT.
Chin EK; Almeida DRP; Velez G; Xu K; Peraire M; Corbella M; Elshatory YM; Kwon YH; Gehrs KM; Boldt HC; Sohn EH; Russell SR; Folk JC; Mahajan VB
Retina; 2017 Jul; 37(7):1345-1351. PubMed ID: 27806001
[TBL] [Abstract][Full Text] [Related]
15. Elevation of intraocular pressure after inadvertent dexamethasone implant injection into the lens.
Lee K; Park A; Jang S; Chung YR
Can J Ophthalmol; 2016 Jun; 51(3):e103-5. PubMed ID: 27316280
[No Abstract] [Full Text] [Related]
16. [Late steroid-induced ocular hypertension after intravitreal dexamethasone implants: A series of 20 cases].
Billant J; Douma I; Agard E; Levron A; Bouvarel H; Leroux P; Badri Y; Dot C
J Fr Ophtalmol; 2023 Nov; 46(9):1039-1046. PubMed ID: 37758545
[TBL] [Abstract][Full Text] [Related]
17. Secondary glaucoma after intravitreal dexamethasone 0.7 mg implant in patients with retinal vein occlusion: a one-year follow-up.
Meyer LM; Schönfeld CL
J Ocul Pharmacol Ther; 2013; 29(6):560-5. PubMed ID: 23480270
[TBL] [Abstract][Full Text] [Related]
18. Severe intraocular pressure response to periocular or intravitreal steroid treatment in Australia and New Zealand: data from the Australian and New Zealand Ophthalmic Surveillance Unit.
Fitzgerald JT; Saunders L; Ridge B; White AJ; Goldberg I; Clark B; Mills RA; Craig JE
Clin Exp Ophthalmol; 2015 Apr; 43(3):234-8. PubMed ID: 25214011
[TBL] [Abstract][Full Text] [Related]
19. Surgical intervention of steroid-induced ocular hypertension from Ozurdex.
Sejpal P; Scott-Weideman J
Optom Vis Sci; 2013 Jan; 90(1):e24-30. PubMed ID: 23241827
[TBL] [Abstract][Full Text] [Related]
20. Predicting the safety zone for steroid-induced ocular hypertension induced by intravitreal dexamethasone implantation.
Choi W; Bae HW; Shin HJ; Kim EW; Kim CY; Kim M; Seong GJ
Br J Ophthalmol; 2022 Aug; 106(8):1150-1156. PubMed ID: 33737305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
